Literature DB >> 19318229

Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.

Joyce E Nutt1, Kieran O'Toole, David Gonzalez, John Lunec.   

Abstract

Clinical outcome following chemotherapy for malignant pleural mesothelioma is poor and improvements are needed. This preclinical study investigates the effect of five tyrosine kinase inhibitors (PTK787, ZD6474, ZD1839, SU6668 and SU11248) on the growth of three mesothelioma cell lines (NCI H226, NCI H28 and MSTO 211H), the presence of growth factor receptors and inhibition of their downstream signalling pathways. GI50 values were determined: ZD6474 and SU11248, mainly VEGFR2 inhibitors, gave the lowest GI50 across all cell lines (3.5-6.9 microM) whereas ZD1839 gave a GI50 in this range only in H28 cells. All cell lines were positive for EGFR, but only H226 cells were positive for VEGFR2 by Western blotting. ZD6474 and ZD1839 inhibited EGF-induced phosphorylation of EGFR, AKT and ERK, whereas VEGF-induced phosphorylation of VEGFR2 was completely inhibited with 0.1 microM SU11248. VEGFR2 was detected in tumour samples by immunohistochemistry. VEGFR2 tyrosine kinase inhibitors warrant further investigation in mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318229     DOI: 10.1016/j.ejca.2009.02.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.

Authors:  Markku Miettinen; Maarit-Sarlomo Rikala; Janusz Rys; Jerzy Lasota; Zeng-Feng Wang
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

Review 2.  Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.

Authors:  Roberto E Favoni; Antonio Daga; Paolo Malatesta; Tullio Florio
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.

Authors:  Daniela Stoppoloni; Claudia Canino; Irene Cardillo; Alessandra Verdina; Alfonso Baldi; Ada Sacchi; Rossella Galati
Journal:  Mol Cancer       Date:  2010-02-02       Impact factor: 27.401

4.  Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.

Authors:  Lindsay A Marek; Trista K Hinz; Anne von Mässenhausen; Kyle A Olszewski; Emily K Kleczko; Diana Boehm; Mary C Weiser-Evans; Raphael A Nemenoff; Hans Hoffmann; Arne Warth; Joseph M Gozgit; Sven Perner; Lynn E Heasley
Journal:  Mol Cancer Res       Date:  2014-06-25       Impact factor: 5.852

5.  Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.

Authors:  E Giovannetti; P A Zucali; Y G Assaraf; L G Leon; K Smid; C Alecci; F Giancola; A Destro; L Gianoncelli; E Lorenzi; M Roncalli; A Santoro; G J Peters
Journal:  Br J Cancer       Date:  2011-10-04       Impact factor: 7.640

6.  Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro.

Authors:  Gaku Moriyama; Maya Tanigawa; Kosuke Sakai; Yusuke Hirata; Satoshi Kikuchi; Yuriko Saito; Hiroyuki Kyoyama; Kuniko Matsuda; Masahiro Seike; Akihiko Gemma; Kazutsugu Uematsu
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

7.  Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow.

Authors:  Ildiko Kovacs; Edina Bugyik; Katalin Dezso; Julia Tarnoki-Zach; Elod Mehes; Marton Gulyas; Andras Czirok; Elisabeth Lang; Michael Grusch; Karin Schelch; Balazs Hegedus; Ildiko Horvath; Nandor Barany; Zsolt Megyesfalvi; Anna Tisza; Zoltan Lohinai; Mir Alireza Hoda; Konrad Hoetzenecker; Francesco Pezzella; Sandor Paku; Viktoria Laszlo; Balazs Dome
Journal:  Transl Lung Cancer Res       Date:  2022-06

8.  Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas.

Authors:  Mutlay Sayan; Arti Shukla; Maximilian B MacPherson; Sherrill L Macura; Jedd M Hillegass; Timothy N Perkins; Joyce K Thompson; Stacie L Beuschel; Jill M Miller; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.